BuyCancerDrugs.com BuyCancerDrugs.com
BuyCancerDrugs.com BuyCancerDrugs.com
OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer
Search OncologyJournal.org
Browse by Cancer Type or Cancer Drug

Go Back   OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer > Blogs > admin
Connect with Facebook


Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
Old

ABRAXANE® Approved for Marketing in Japan for Breast Cancer

Posted 07-23-2010 at 03:13 PM by admin
July 23, 2010 09:00 AM Eastern Daylight Time

– Product Launch Planned for September; ABRAXANE Now Approved in 40 Countries –

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE® IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment...
Administrator
Comments 0 admin is offline
Old

Sci. Present. Exploring ABRAXANE’s Exp. Potential in Mult. Diff-to-Treat Cancers

Posted 05-18-2010 at 02:31 PM by admin
Over 30 Scientific Presentations at ASCO Exploring ABRAXANE’s Expanded Potential in Multiple Difficult-to-Treat Cancers

Clinical Data in Lung, Pancreatic, Melanoma, Ovarian, Head & Neck, Bladder and Triple-Negative Breast Cancers to be Presented at 46th Meeting of the American Society of Clinical Oncology

May 18, 2010 08:05 AM Eastern Daylight Time

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII) today announced that 32 scientific...
Administrator
Comments 0 admin is offline
Old

Abraxis to Pres. Phase I/II Pancreatic Survival Data at 101st Annual Meeting of AACR

Posted 04-12-2010 at 05:22 PM by admin
Abraxis to Present Phase I/II Pancreatic Survival Data at 101st Annual Meeting of the American Association for Cancer Research

April 08, 2010 03:45 PM Eastern Daylight Time

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)...
Administrator
Comments 0 admin is offline
Old

Genasense with Temodar & Abraxane Shows Preliminary Evidence of High Response Rates

Posted 06-04-2009 at 07:36 PM by admin
Genasense® Combined with Temodar® and Abraxane® Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma

One-hour Infusion Schedule to be Tested in Next Cohort

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company’s lead oncology product, Genasense®...
Administrator
Comments 0 admin is offline
Old

Drugs Added to Lung Cancer Treatment Guidelines: Presented at NCCN

Posted 03-17-2009 at 02:57 PM by admin
By Ed Susman

HOLLYWOOD, Florida -- March 13, 2009 -- Several new drugs could be added to the arsenal of weapons used to combat recurrent or metastatic non-small-cell lung cancer, doctors stated here at the National Comprehensive Cancer Network (NCCN) 14th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care.

More than a dozen cytotoxic and targeted agents can now be considered in battling the disease, noted David S. Ettinger, MD, Sidney Kimmel Comprehensive...
Administrator
Comments 0 admin is offline


All times are GMT. The time now is 02:13 PM.


Powered by vBulletin® Version 3.8.1
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.